Conoidin A

Conoidin A is a cell permeable inhibitor of T. gondii enzyme peroxiredoxin II (TgPrxII) with nematicidal properties. Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC50 of 23 μM. Conoidin A also inhibits hyperoxidation of mammalian PrxI and PrxII (but not PrxIII) [1][2]. Conoidin A has antioxidant, neuroprotective effects and can be used for the research of ischaemic heart disease[3].

Product Specifications

CAS Number

[18080-67-6]

UNSPSC

12352005

Hazard Statement

H302, H314

Target

Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/conoidin-a.html

Concentration

10mM

Purity

99.32

Solubility

DMSO : 14.29 mg/mL (ultrasonic)

Smiles

[O-][N+]1=C(C(CBr)=[N+](C2=C1C=CC=C2)[O-])CBr

Molecular Formula

C10H8Br2N2O2

Molecular Weight

347.99

Precautions

H302, H314

References & Citations

[1]Jeralyn D Haraldsen, et al. IDENTIFICATION OF CONOIDIN A AS A COVALENT INHIBITOR OF PEROXIREDOXIN II. Org Biomol Chem. 2009;7:3040-3048.|[2]Gu Liu, et al. Optimisation of conoidin A, a peroxiredoxin inhibitor. ChemMedChem. 2010 Jan;5 (1) :41-5.|[3]Bo Wei, et al. Luteolin ameliorates rat myocardial ischaemia-reperfusion injury through activation of peroxiredoxin II. Br J Pharmacol